Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2025)

Cartesian Therapeutics (RNAC) has 3 years of Other Operating Expenses data on file, last reported at $56.7 million in Q4 2025.

• On a quarterly basis, Other Operating Expenses rose 648.12% year-over-year to $56.7 million in Q4 2025; TTM through Mar 2026 was $56.7 million, a 648.12% increase from a year earlier, with the FY2025 full-year figure at $56.7 million, up 648.12% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $56.7 million, up from $7.6 million in the prior quarter.
• Over the last five years, Other Operating Expenses for RNAC reached as high as $56.7 million in Q4 2025 and fell as low as $710000.0 in Q4 2023.
• Historically, Other Operating Expenses has averaged $21.7 million across 3 years, with a median of $7.6 million in 2024.
• Across the five-year window, Other Operating Expenses jumped 967.46% in 2024 and soared 648.12% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $710000.0 in 2023, then soared by 967.46% to $7.6 million in 2024, then surged by 648.12% to $56.7 million in 2025.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $56.7 million in Q4 2025, $7.6 million in Q4 2024, and $710000.0 in Q4 2023.